MedTrace Logo

Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF)

NCT03096613 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2018-03-29

No results posted yet for this study

Summary

Based on accumulating evidence showing that hypothyroid status is associated with poor prognosis among heart failure (HF) patients, the study is designed to evaluate whether replacement treatment with levothyroxine could have beneficial effects on patients with HF and subclinical hypothyroidism. The study is a prospective, randomized, parallel-group trial to assess the efficacy and safety of levothyroxine replacement on evidence-based HF standard therapy in stable chronic heart failure patients with subclinical hypothyroidism.

Conditions

Interventions

DRUG

Levothyroxine

Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.

Sponsors & Collaborators

  • The Luhe Teaching Hospital of the Capital Medical University

    collaborator OTHER

  • Tianjin Medical University Second Hospital

    collaborator OTHER

  • The First Hospital of Hebei Medical University

    collaborator OTHER

  • Henan Provincial People's Hospital

    collaborator OTHER

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    lead OTHER

Principal Investigators

  • Yi-Da Tang, MD, PhD · Chinese Academy of Medical Sciences, Fuwai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-18
Primary Completion
2019-02-28
Completion
2019-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03096613 on ClinicalTrials.gov